Intensive insulin therapy

Global Insulin Infusion Pumps Market - Growth, Trends and Forecasts (2012-2024): Medtronic is Expected to Remain Dominant During 2019-2024 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 2, 2019
Health, Medical devices, Diabetes, Endocrine system, Medicine, Eli Lilly and Company, Clinical medicine, Peptide hormones, Recombinant proteins, Insulin pump, Diabetes, Insulin, Animas Corporation, Intensive insulin therapy

The "Insulin Infusion Pumps Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Insulin Infusion Pumps Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
  • The global insulin infusion pump market is set to witness a CAGR of 7.51% during the forecast period.
  • Now, insulin pumps can control the algorithm that automatically delivers the insulin, after analyzing the blood glucose reading.
  • Animas had to exit the insulin pump market, as the company has admitted that rising competition was the reason for them to leave the market.

The global insulin delivery devices market is expected to reach US$ 22,830.0 Mn by 2025 from US$ 11,869.0 Mn in 2017

Retrieved on: 
Tuesday, April 2, 2019
Eli Lilly and Company, Medicine, Endocrine system, Clinical medicine, Insulin pump, Insulin pen, Insulin, Syringe, Intensive insulin therapy, Insulin analog

NEW YORK, April 1, 2019 /PRNewswire/ -- The global insulin delivery devices market is expected to reach US$ 22,830.0 Mn by 2025 from US$ 11,869.0 Mn in 2017.

Key Points: 
  • NEW YORK, April 1, 2019 /PRNewswire/ -- The global insulin delivery devices market is expected to reach US$ 22,830.0 Mn by 2025 from US$ 11,869.0 Mn in 2017.
  • The growth of the insulin delivery devices market is primarily attributed to the rise in obesity and increasing technological advancement in insulin delivery devices are the major factors that are anticipated to propel the growth for the insulin delivery devices market.However, complications and risk associated with the delivery of insulin expected to act as major challenges hindering the market growth.
  • On the other hand, growing product innovations is expected to be prevalent future trend in the global insulin delivery devices market.
  • Global insulin delivery devices market, based on the product was segmented into insulin pens, insulin pumps, insulin syringes, pen needles and others.The insulin pens segment is further segmented into reusable insulin pens and disposable insulin pens segments.

Lilly to Introduce Lower-Priced Insulin

Retrieved on: 
Monday, March 4, 2019
Eli Lilly and Company, Endocrine system, Branches of biology, Hormones, Peptide hormones, Recombinant proteins, Diabetes, RTT, Insulin, Insulin analog, Intensive insulin therapy

Introducing an alternative insulin option allows Lilly to provide a lower-priced insulin more quickly while providing payers time to renegotiate downstream contracts and adjust to new system economics.

Key Points: 
  • Introducing an alternative insulin option allows Lilly to provide a lower-priced insulin more quickly while providing payers time to renegotiate downstream contracts and adjust to new system economics.
  • In addition to the introduction of Lilly's Insulin Lispro, we have taken several other steps to lower what people pay for insulin.
  • More than 10,000 people each month are paying significantly less for their Lilly insulin through the Solution Center and other offerings.
  • Do not take Humalog or Insulin Lispro if your blood sugar is too low (hypoglycemia) or if you are allergic to Humalog or Insulin Lispro or any of the ingredients in Humalog or Insulin Lispro.

Hygieia Receives 510(k) Clearance from FDA for Phone App That Enhances Company's d-Nav Insulin Guidance Service

Retrieved on: 
Wednesday, February 20, 2019
Endocrine system, Medicine, Branches of biology, Eli Lilly and Company, Diabetes, Peptide hormones, Recombinant proteins, Insulin, RTT, Glucose meter, Intensive insulin therapy, Insulin pump

It is also the first insulin-titration app that can connect to any glucose meter that shares data with the cloud.

Key Points: 
  • It is also the first insulin-titration app that can connect to any glucose meter that shares data with the cloud.
  • The d-Nav Service, including the user-friendly phone app, makes insulin therapy more effective, less time intensive and less costly for everyone involved."
  • Patients utilizing the Service can use the phone app to enter glucose event data and receive a recommended insulin dose.
  • Hygieia is a digital insulin enhancement company dedicated to making insulin therapy easier and more effective for everyone involved.

Mellitus Health Wins Best Abstract Award at 3rd World Congress on Clinical Trials in Diabetes

Retrieved on: 
Monday, January 14, 2019
Technology, Data management, Hardware, Software, Health, Biotechnology, Clinical trials, Medical devices, Pharmaceutical, Mobile, Wireless, Research, Diabetes, Science, Endocrine system, Medicine, Diabetes, Endocrinology, Eli Lilly and Company, Peptide hormones, Recombinant proteins, Blood tests, Insulin, Glycated hemoglobin, Intensive insulin therapy, Diabetes management

Mellitus Health won the Best Abstract Award at the 3rd World Congress on Clinical Trials in Diabetes in Vienna in December, 2018, for a study that featured Insulin Insights, its clinical therapeutic.

Key Points: 
  • Mellitus Health won the Best Abstract Award at the 3rd World Congress on Clinical Trials in Diabetes in Vienna in December, 2018, for a study that featured Insulin Insights, its clinical therapeutic.
  • The Congress selected the award based on scientific quality, novelty/innovation, advancement of the field/impact, and relevance.
  • The abstract detailed the 2.4% reduction in HbA1c (a measure of average blood glucose) in six months achieved among insulin-using patients with poorly controlled diabetes when nurse practitioners used Mellitus Healths insulin dosing clinical therapeutic, Insulin Insights, to guide their decision-making.
  • Glucometers connected to mobile phones automatically transmitted patients blood glucose levels to Mellitus Healths Insulin Insights clinical therapeutic, which provided clinicians with periodic recommendations about how to adjust patients insulin regimens.

Global Insulin Pens Market 2018-2023 - Rising Strategic Partnerships to Boost Sales of Insulin Pens / Increasing focus on Smart Insulin Pens

Retrieved on: 
Thursday, December 20, 2018
Endocrine system, Medicine, Endocrinology, RTT, Diabetes, Eli Lilly and Company, Peptide hormones, Recombinant proteins, Insulin, Diabetes mellitus, Insulin pump, Intensive insulin therapy

The insulin pens market will register a CAGR of close to 9% by 2023.

Key Points: 
  • The insulin pens market will register a CAGR of close to 9% by 2023.
  • The increasing focus on development of smart insulin pens for type 2 diabetes is likely to drive growth in the market.
  • Factors such as the increasing focus on development of smart insulin pens and the incidences of diabetes, will provide considerable growth opportunities to insulin pens manufactures.
  • The latest trend gaining momentum in the market is the increasing focus on development of smart insulin pens for type 2 diabetes.